Skip to content
Vivo logo
← All articles

Compounding Pharmacy Safety: What Patients Should Verify

Compounding Pharmacy Safety: What Patients Should Verify

Isometric illustration of careful medication verification

Compounded medications can be a safe option when a qualified provider prescribes them and a properly licensed pharmacy prepares them. They are also not FDA-approved, and the FDA does not review their safety, effectiveness, or quality before they reach patients. Safety therefore depends on who prescribes, which pharmacy prepares the medication, how that pharmacy is overseen, and whether the patient can verify each of those facts. This guide explains how oversight works in the United States and what to check.

VivoKnow Who Prepares Your TreatmentVivo offers provider-supervised treatments prepared by licensed U.S. pharmacies, with personalized treatment selection and HIPAA-compliant data practices.Explore Vivo treatments

TL;DR

  • Compounded drugs are not FDA-approved, and the FDA does not verify their safety, effectiveness, or quality before marketing.
  • Two categories exist: 503A pharmacies, overseen mainly by state boards of pharmacy, and 503B outsourcing facilities, which follow current good manufacturing practice (CGMP) and face FDA inspection.
  • The main documented risks are contamination and incorrect strength, which is why the pharmacy’s license, inspection record, and accreditation matter.
  • Accreditation is voluntary, so verify the state license first and treat accreditation as an additional signal.
  • A licensed provider should be able to tell you which pharmacy prepares your medication and why a compounded version fits your needs.

Table of Contents

What pharmacy compounding is

The FDA describes compounding as a practice in which a licensed pharmacist, a licensed physician, or, at an outsourcing facility, a person supervised by a licensed pharmacist combines, mixes, or alters ingredients to create a medication tailored to an individual patient. It is a long-standing part of pharmacy practice, not a gray market.

Patients typically need a compounded medication for one of a few reasons. According to Mayo Clinic Press, these include an allergy to an ingredient in a commercial product, difficulty swallowing pills, a drug shortage, or the need for a dose or form that does not exist as a commercial product. A nasal spray, a cream, or a dose adjusted in small steps are common examples of forms a prescriber may request.

Common reasons patients may need compounded medicines

Harvard Health reports that compounded medicines represent up to 3% of all prescriptions, so the practice is common enough that patients benefit from knowing how to evaluate it (Harvard Health, 2024).

Are compounded drugs FDA-approved?

No. The FDA states that compounded drugs are not FDA-approved and that it does not verify their safety, effectiveness, or quality before they are marketed (FDA compounding Q&A). By statute, compounders do not have to show the FDA that their products meet the standards that drug manufacturers must meet, and the agency does not conduct premarket review of compounded drugs (FDA consumer update).

Two details are often misunderstood:

  • The ingredients may be approved, the finished product is not. Mayo Clinic Press notes that individual ingredients may be FDA approved, but the final compounded product is not tested or approved by the FDA the way mass-produced drugs are. Pharmacies are expected to follow U.S. Pharmacopeia (USP) standards and state or federal rules.
  • Registration is not approval. The FDA explains that a 503B facility’s registration means only that the agency received the required registration information. It does not mean the facility makes FDA-approved drugs or complies with CGMP.

This is the regulatory reality behind every compounded prescription, and it is the reason oversight by a licensed prescriber and a licensed pharmacy carries so much weight.

The two types of compounding: 503A and 503B

After a 2012 contamination event, Congress passed the Drug Quality and Security Act (DQSA). The FDA reports that contaminated drugs from a Massachusetts compounder led to more than 750 serious infections and over 60 deaths in 20 states, and the law created the outsourcing facility category with more stringent quality standards.

Feature Section 503A pharmacy Section 503B outsourcing facility
Typical model Traditional pharmacy compounding tied to a patient-specific prescription Larger-scale compounding, registered voluntarily with the FDA
Primary oversight State board of pharmacy FDA, with risk-based inspections
CGMP requirements Not subject to CGMP Subject to CGMP
Adverse event reporting to FDA Not required Required

The table reflects the FDA’s description that drugs from outsourcing facilities are subject to CGMP while drugs compounded under section 503A are not (FDA compounding Q&A). A peer-reviewed overview of the DQSA adds that 503B facilities must report adverse events, submit product information every six months, and pay an annual fee (PMC, 2014). Brookings notes that 503A compounders are not required to report adverse events to the FDA (Brookings, 2024).

Neither category is simply “better.” A 503A pharmacy is the usual route for an individualized prescription written for one patient, and a state-licensed pharmacy answers to its state board. What matters for a patient is that the pharmacy is licensed, inspected under the rules that apply to it, and transparent about its practices. Our clinician-facing article on 503A and 503B shipment checks goes deeper into those distinctions.

The main risks, and what they mean for safe use

The FDA says poor compounding practices can cause contamination or too much or too little active ingredient, which may lead to serious injury or death, and that compounded drugs should be used only when a patient’s medical needs cannot be met by an FDA-approved drug (FDA compounding Q&A). Several specific risk patterns are documented:

  • Quality variation. A peer-reviewed analysis reports that testing to assess quality of compounded products is inconsistent and that independent testing has shown compounded drugs failing specifications at a higher rate than approved drugs (Gudeman et al., 2013).
  • Dosing errors with injectables. In July 2024 the FDA warned that patients had overdosed on compounded semaglutide injections, with some taking up to 20 times the intended dose, according to Ars Technica’s report. Dosing units and syringe instructions are a point to confirm with the prescriber before the first injection.
  • Unapproved ingredient forms. Harvard Health reports that in 2023 the FDA received reports of compounders using semaglutide salt forms that are not FDA-approved and lack evidence of safety or effectiveness.
  • Shipping and labeling. Medscape reports that FDA concerns about unapproved GLP-1 drugs include improper storage during shipping and false labeling on fraudulent products (Medscape, 2026).

The practical conclusion is not to avoid compounded medication categories, but to choose a licensed prescriber, a licensed U.S. pharmacy, and a dispensing process that explains dose, storage, and what to do if something looks wrong. Patients can report problems to the FDA, and the agency runs a risk alert program for compounding concerns. Our article on glutathione injection side effects shows how product-specific safety information is handled for one of the injectables we discuss.

Accreditation: what it signals and what it does not

Accreditation is a common search topic, and it is useful when understood correctly. Two organizations run voluntary programs for compounding pharmacies. PCAB, operated by ACHC, verifies compliance with USP compounding standards, including sterile and nonsterile preparations and hazardous-drug handling. The NABP program evaluates alignment with USP standards and section 503A requirements (LegalClarity, 2026).

Because both programs are voluntary, a pharmacy without a listing is not automatically unsafe, and a badge on a website is not a substitute for a state license. Treat accreditation as one signal among several:

  1. State license first. A state board of pharmacy record shows whether the license is active and whether discipline has been recorded. Our guide to state pharmacy license checks explains why state records come before website badges.
  2. Accreditation directories second. Look up the pharmacy in the PCAB and NABP directories rather than relying on a logo.
  3. Inspection history third. The FDA cautions that even a recent satisfactory inspection is only a snapshot in time, and that it reviews a sample of records, so buyers should look at other information about the facility as well.

An important point for mail-order patients is that the pharmacy type affects what a registration or license establishes. A plain-language explanation of how mail order pharmacy safety works, including how traditional pharmacies differ from registered outsourcing facilities, helps frame what these labels do and do not guarantee.

A checklist before you start a compounded prescription

For telehealth patients, who never visit the pharmacy, the checks happen online and on the phone. These questions are reasonable to ask any provider:

  • Who prescribes? The prescriber should be a licensed clinician who reviews your history and orders any labs the treatment warrants.
  • Which pharmacy compounds the medication? The provider should name the pharmacy so you can look up its state license.
  • Is the pharmacy 503A or 503B, and licensed in which states? Ask for the type and the state board that oversees it.
  • Why a compounded version? The FDA’s position is that an approved drug is preferred when a patient can use one. The prescriber should explain the clinical reason a compounded preparation fits, such as a specific form, dose, or availability.
  • What are the dose, units, and storage instructions? For injections especially, confirm the concentration, the volume to draw, and how to store the product on arrival.
  • How is follow-up handled? Ongoing provider supervision means someone reviews your response and answers questions about side effects.
  • How is your health data protected? Ask whether the service follows HIPAA privacy standards.

The Harvard Health physician quoted in that article advises using a compounding pharmacy when you need a medication that is not commercially available, and notes that you may not be getting exactly the product you assume because formulations are not reviewed by the FDA for purity, safety, or effectiveness. The checklist above is how patients narrow that uncertainty. The FDA also encourages consumers to research online pharmacies before using them, including through its BeSafeRx resource (FDA compounding Q&A).

Why compounded medications are priced and covered differently

Compounded prescriptions are typically paid for directly by patients, and many telehealth services publish a monthly or quarterly plan price instead of billing insurance. Coverage rules vary by plan, so a patient who wants to use insurance should ask the insurer directly about compounded products. Comparing the published plan price, what it includes (provider review, medication, shipping, refills), and the billing period is a more reliable way to compare services than comparing per-dose figures.

Our perspective

We approach compounding pharmacy safety as a question of verification, not reassurance. Compounded therapies are not FDA-approved, and we say so plainly. What a patient can control is who prescribes, which pharmacy prepares the medication, and whether each of those can be checked.

At Vivo, treatment selection is guided and provider-supervised, and our prescriptions are prepared by licensed U.S. pharmacies and delivered to the patient’s door. Provider review comes before a treatment plan is approved, and ongoing oversight continues through refills. We handle patient information under HIPAA-compliant practices because health privacy is part of safety, not an add-on.

We encourage patients to ask us the questions in the checklist above. A telehealth service that welcomes questions about the prescriber, the pharmacy, dosing, and storage is one that is built for supervised care, and this is the standard we hold ourselves to.

Jack

Treatment plans with provider supervision

Patients who want a supervised, telehealth route can review our published plans. Current monthly plan prices include NAD+ Nasal Spray at $119 per month, Sermorelin at $135 per month, and MIC+B12 at $109 per month. Our weight management programs, including compounded semaglutide and tirzepatide, are reviewed by a licensed provider before approval. Plans are prepared by licensed U.S. pharmacies and shipped to your home, and the provider can answer pharmacy and dosing questions during intake.

FAQ

Is a compounding pharmacy safe?

It can be, when a licensed pharmacist prepares the medication for a patient with a valid prescription and the pharmacy follows the rules that apply to it. The FDA notes that poor practices can cause contamination or incorrect strength, so patients should verify the pharmacy’s state license and ask the prescriber how the medication is prepared, dosed, and stored.

Are compounded drugs FDA-approved?

No. The FDA does not approve compounded drugs and does not verify their safety, effectiveness, or quality before marketing. The ingredients used are expected to meet quality standards, but the finished compounded product has not gone through FDA premarket review.

How do I check a compounding pharmacy’s accreditation?

Start with the state board of pharmacy license record, then search the PCAB (ACHC) and NABP accreditation directories. Accreditation is voluntary, so its absence alone does not show a problem, and its presence does not replace a valid state license.

What is the difference between a compounding pharmacy and a regular pharmacy?

A regular pharmacy dispenses manufactured, FDA-approved products, while a compounding pharmacy prepares a medication for an individual patient by combining or altering ingredients. Compounding pharmacies operating under section 503A are overseen mainly by state boards, and 503B outsourcing facilities are inspected by the FDA.

Sources